There are currently 191 clinical trials in Fort Myers, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Florida Cancer Specialists, Golisano Children's Hospital of Southwest Florida, Lee Memorial Health System and Florida Cancer Specialists South. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Recruiting
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Gender:
All
Ages:
12 years and above
Trial Updated:
03/12/2024
Locations: Florida Cancer Specialists South Division, Fort Myers, Florida +2 locations
Conditions: Solid Tumor, Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Fort Myers, Florida
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Recruiting
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the RP2D of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer. The study will furth... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Florida Cancer Specialists, Fort Myers, Florida
Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma
Project: Every Child for Younger Patients With Cancer
Recruiting
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Gender:
All
Ages:
25 years and below
Trial Updated:
02/27/2024
Locations: Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida
Conditions: Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Lymphoproliferative Disorder, Myeloproliferative Neoplasm, Stromal Neoplasm, Carcinoma In Situ, Malignant Solid Neoplasm, Desmoid Fibromatosis, Ganglioneuroma, Melanocytic Neoplasm, Neuroendocrine Neoplasm
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors
Recruiting
This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
02/27/2024
Locations: Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida
Conditions: Central Nervous System Carcinoma
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Recruiting
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
Gender:
All
Ages:
Between 18 years and 84 years
Trial Updated:
02/23/2024
Locations: Nicox Clinical Site, Fort Myers, Florida
Conditions: Open Angle Glaucoma, Ocular Hypertension
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Recruiting
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
Gender:
Female
Ages:
Between 25 years and 100 years
Trial Updated:
02/20/2024
Locations: Florida Gynecologic Oncology, Fort Myers, Florida
Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer
Recruiting
This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and unresectable or metastatic pancreatic adenocarcinoma. Subjects who are eligible to receive two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), routinely prescribed in combination for pancreatic cancer may be included in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Florida Cancer Specialists, Fort Myers, Florida
Conditions: Metastatic Pancreatic Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
Recruiting
This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2/3).
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Florida Gynecologic Oncology, Fort Myers, Florida
Conditions: Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
Recruiting
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/14/2024
Locations: Covenant Metabolic Specialist LLC, Fort Myers, Florida
Conditions: Primary Biliary Cirrhosis
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Recruiting
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: SCRI - Florida Cancer Specialists South, Fort Myers, Florida
Conditions: Non Small Cell Lung Cancer
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
Recruiting
A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/09/2024
Locations: Southwest General Healthcare Center, Fort Myers, Florida
Conditions: Type 2 Diabetes Mellitus